NYU Langone Health

Company

Related News

BioNTech, BioLineRx Unveil Clinical Data at ASCO 2026

BioNTech presented phase 2 data for HER2-directed ADC Trastuzumab Pamirtecan showing 47.9% response rate in endometrial cancer, with FDA submission planned for 2026. BioLineRx dosed first patient in phase 1/2a GLIX1 trial for glioblastoma and reported new preclinical data. Both companies presented at ASCO 2026.

Related Clinical Trials

NCT ID Title Status Phase
NCT07612215

Elacestrant in Advanced Triple Positive Breast Cancer

RECRUITING PHASE1/PHASE2
NCT07607938

Psilocybin as a Novel Therapy for Residual Anhedonia

NOT_YET_RECRUITING PHASE1
NCT07607522

Cardiac Rehab Referral Nudges

NOT_YET_RECRUITING
NCT07602517

Guselkumab for Overlap Inflammatory Bowel Disease and Spondyloarthritis

NOT_YET_RECRUITING
NCT07601828

Oxygen Delivery Index (ODIN) Study

NOT_YET_RECRUITING NA
NCT07598357

Salvaged Red Blood Cell Transfusion During Pancreatic Adenocarcinoma Operations

NOT_YET_RECRUITING NA
NCT07586241

Vascular Endothelial Inflammation and Health Status In INOCA (VISION-INOCA)

NOT_YET_RECRUITING
NCT07572526

tDCS: Sleep to Mood in Depression (S2M-D)

NOT_YET_RECRUITING NA
NCT07571239

Altius Peripheral Nerve Stimulation in Amputees After TMR/RPNI

NOT_YET_RECRUITING NA
NCT07567027

Improving Cryoablation Efficacy With BARRigel Rectal Spacing (ICE-BARR)

NOT_YET_RECRUITING NA